330 related articles for article (PubMed ID: 30133144)
21. Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.
Nakasuka T; Ichihara E; Makimoto G; Maeda Y; Kiura K
J Thorac Oncol; 2019 Aug; 14(8):e168-e169. PubMed ID: 31345339
[No Abstract] [Full Text] [Related]
22. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract][Full Text] [Related]
23. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
24. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
[TBL] [Abstract][Full Text] [Related]
25. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
Tao H; Liu Z; Mu J; Gai F; Huang Z; Shi L
Diagn Pathol; 2022 Feb; 17(1):27. PubMed ID: 35144623
[TBL] [Abstract][Full Text] [Related]
26. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
27. Concomitance of a novel RMDN2-ALK fusion and an EML4-ALK fusion in a lung adenocarcinoma.
Jiang L; Chen S; Stinnett V; Haley L; Morsberger L; Shane A; Hardy M; Smith K; Gocke CD; Lin MT; Zou YS
Cancer Genet; 2021 Nov; 258-259():18-22. PubMed ID: 34233240
[TBL] [Abstract][Full Text] [Related]
28. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
29. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
Wang T; Du G; Niu M; Liu R
BMC Pulm Med; 2023 Feb; 23(1):60. PubMed ID: 36755262
[TBL] [Abstract][Full Text] [Related]
30. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK
Christopoulos P; Endris V; Bozorgmehr F; Elsayed M; Kirchner M; Ristau J; Buchhalter I; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Warth A; Bischoff H; Schirmacher P; Stenzinger A; Thomas M
Int J Cancer; 2018 Jun; 142(12):2589-2598. PubMed ID: 29363116
[TBL] [Abstract][Full Text] [Related]
31. Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib.
Qin BD; Jiao XD; Liu K; Wu Y; Zang YS
J Thorac Oncol; 2019 Jun; 14(6):e115-e117. PubMed ID: 31122560
[No Abstract] [Full Text] [Related]
32. A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.
Tamiya A; Shimizu S; Atagi S
J Thorac Oncol; 2015 Aug; 10(8):e74. PubMed ID: 26200283
[No Abstract] [Full Text] [Related]
33. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
34. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
[TBL] [Abstract][Full Text] [Related]
35. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
Lin J; Wang W; Lin J; Chen R; Cao Y
J Cell Mol Med; 2022 Oct; 26(20):5326-5329. PubMed ID: 36102237
[TBL] [Abstract][Full Text] [Related]
36. A novel
Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
[TBL] [Abstract][Full Text] [Related]
37. Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.
Gong J; Gregg JP; Ma W; Yoneda K; Moore EH; Daly ME; Zhang Y; Williams MJ; Li T
J Natl Compr Canc Netw; 2019 Apr; 17(4):297-301. PubMed ID: 30959466
[TBL] [Abstract][Full Text] [Related]
38. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
39. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
Nagasaka M; Fisher A; Chowdhury T; Ge Y; Sukari A
Clin Lung Cancer; 2021 Jan; 22(1):e51-e53. PubMed ID: 32893122
[No Abstract] [Full Text] [Related]
40. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
Tsuji T; Ozasa H; Aoki W; Aburaya S; Funazo T; Furugaki K; Yoshimura Y; Ajimizu H; Okutani R; Yasuda Y; Nomizo T; Uemasu K; Hasegawa K; Yoshida H; Yagi Y; Nagai H; Sakamori Y; Ueda M; Hirai T; Kim YH
Mol Cancer Res; 2019 Jan; 17(1):212-224. PubMed ID: 30171175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]